Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 5, 2016, Pages 865-871

  Zhang, Ting Juan ^a   Zhou, Jing Dong ^a   Yang, Dong Qin ^a   Wang, Yu Xin ^a   Yao, Dong Ming ^a   Ma, Ji Chun ^a   Wen, Xiang Mei ^a   Guo, Hong ^a   Lin, Jiang ^a   Qian, Jun ^a  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

DLX4; hypermethylation; myelodysplastic syndrome (MDS); prognosis

Indexed keywords

BISULFITE; HEMOGLOBIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DLX4; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DLX4 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; KARYOTYPE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTE; WORLD HEALTH ORGANIZATION; DNA METHYLATION; GENETICS; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; COHORT STUDIES; DNA METHYLATION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84966588626     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0536     Document Type: Article

References (30)

1. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013;122:4021-34.
2. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012;12:849-59.
3. Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev 2013;27:243-59.
4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
5. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315-25.
6. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002;2:777-85.
7. Kraus P, Lufkin T. Dlx homeobox gene control of mammalian limb and craniofacial development. Am J Med Genet A 2006;140:1366-74.
8. Haga SB, Fu S, Karp JE, Ross DD, Williams DM, Hankins WD, et al. BP1, a new homeobox gene, is frequently expressed in acute leukemias. Leukemia 2000;14:1867-75.
9. Yu M, Wan YF, Zou QH. Prognostic significance of BP1 mRNA expression level in patients with non-small cell lung cancer. Clin Biochem 2008;41:824-30.
10. Yu M, Yang Y, Shi Y, Wang D, Wei X, Zhang N, et al. Expression level of beta protein 1 mRNA in Chinese breast cancer patients: a potential molecular marker for poor prognosis. Cancer Sci 2008;99:173-8.
11. Gao Y, Li Z, Guo X, Liu Y, Zhang K. DLX4 as a prognostic marker for hepatocellular carcinoma. Neoplasma 2014;61:318-23.
12. Miyamoto K, Fukutomi T, Akashi-Tanaka S, Hasegawa T, Asahara T, Sugimura T, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer 2005;116:407-14.
13. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, et al. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 2010;5:499-508.
14. Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD, Pfeifer GP. DNA methylation biomarkers for lung cancer. Tumor Biol 2012;33:287-96.
15. Sakane J, Taniyama K, Miyamoto K, Saito A, Kuraoka K, Nishimura T, et al. Aberrant DNA methylation of DLX4 and SIM1 is a predictive marker for disease progression of uterine cervical low-grade squamous intraepithelial lesion. Diagn Cytopathol 2015;43:462-70.
16. Harada H, Miyamoto K, Yamashita Y, Taniyama K, Ohdan H, Okada M. Methylated DLX4 predicts response to pathologic stage I non-small cell lung cancer resection. Ann Thorac Surg 2015;99:1746-54.
17. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008.
18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
19. Tang CY, Lin J, Qian W, Yang J, Ma JC, Deng ZQ, et al. Low SOX17 expression: prognostic significance in de novo acute myeloid leukemia with normal cytogenetics. Clin Chem Lab Med 2014;52:1843-50.
20. Qian J, Chen XX, Qian W, Yang J, Wen XM, Ma JC, et al. Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome. Clin Chem Lab Med 2014;52:1859-65.
21. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2011;6:e26906.
22. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 2012;91:519-25.
23. Qian J, Yao DM, Lin J, Qian W, Wang CZ, Chai HY, et al. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2012;7:e45760.
24. Yang J, Qian J, Lin J, Yang XF, Qian W, Chen Q, et al. Development of a high-resolution melting analysis for the detection of the SF3B1 mutations. Genet Test Mol Biomarkers 2013;17:342-7.
25. Wen XM, Hu JB, Yang J, Qian W, Yao DM, Deng ZQ, et al. CEBPA methylation and mutation in myelodysplastic syndrome. Med Oncol 2015;32:605.
26. Wen XM, Lin J, Yang J, Yao DM, Deng ZQ, Tang CY, et al. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. Int J Clin Exp Pathol 2014;7:6832-40.
27. Zhang L, Yang M, Gan L, He T, Xiao X, Stewart MD, et al. DLX4 upregulates TWIST and enhances tumor migration, invasion and metastasis. Int J Biol Sci 2012;8:1178-87.
28. Sun Y, Lu X, Yin L, Zhao F, Feng Y. Inhibition of DLX4 promotes apoptosis in choriocarcinoma cell lines. Placenta 2006;27:375-83.
29. Awwad RT, Do K, Stevenson H, Fu SW, Lo-Coco F, Costello M, et al. Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells. Ann Hematol 2008;87:195-203.
30. Zhou JD, Wang YX, Zhang TJ, Yang DQ, Yao DM, Guo H, et al. Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia. Biochem Biophys Res Commun 2015;463:1250-6.